Navigation Links
Dr. Mark Nestor Presents on Pyratine-6(TM) at the South Beach Symposium

NAPA, Calif., Feb. 21 /PRNewswire-FirstCall/ -- Senetek PLC (OTC Bulletin Board: SNKTY), a Life Sciences company engaged in the development of technologies that target the science of healthy aging, today announced that Dr. Mark Nestor presented on Pyratine-6(TM) at the 6th Annual South Beach Symposium in Miami.

In his presentation to leading dermatologists at the Symposium, Dr. Nestor outlined the attributes of Pyratine-6(TM) for the treatment of photodamaged skin as demonstrated in clinical trial results. Pyratine-6(TM) achieved significant improvement in skin roughness, increased skin moisture content and reduced erythema (redness due to capillary congestion) in as early as two weeks. In addition, Pyratine-6(TM) was shown to reduce mottled hyperpigmentation and fine wrinkles and was well tolerated by patients, with none of the skin irritation reported for retinoids and alpha hydroxyl acids. Based on positive results demonstrated in clinical evaluations, Pyratine-6(TM) is currently in clinical trials for the treatment of acne rosacea.

Mark S. Nestor, MD, PhD is a Clinical Associate Professor of the Department of Dermatology and Cutaneous Surgery at the University of Miami Miller School of Medicine. He serves as Director of the Center for Cosmetic Enhancement and Director of the Center for Clinical and Cosmetic Studies in Aventura, Florida. In addition, Dr. Nestor is Co-Chairman of the Board of Directors of Advanced Dermatology Management, a physician practice management company, and is currently the immediate past President of the International Society for Cosmetic and Laser Surgeons. He is the President of the American Society for Photodynamic Therapy and a Past President of the Florida Society of Dermatology and Dermatologic Surgery. Dr. Nestor is recognized as a world expert in cutaneous laser surgery, photodynamic therapy as well as the use of fillers and toxins in aesthetic medicine.

Frank Massino, Chairman and Chief Executive Officer of Senetek stated, "Pyratine-6(TM) has been well received by the dermatological community, and we are pleased that the compound is soon to complete additional clinical evaluation for the treatment of acne rosacea, a chronic dermatosis afflicting more than 45 million people worldwide."

About Senetek PLC

Senetek PLC (OTC Bulletin Board: SNKTY) is a Life Sciences company engaged in the development of breakthrough technologies that target the science of healthy aging. The Company's extensive research collaborations have resulted in a strong pipeline of patented compounds and products with broad therapeutic applications and a leading presence in dermatology. Senetek collaborates with established specialty pharmaceutical companies in the final development and marketing of its proprietary products, most recently resulting in the development of the best-selling anti-aging product sold in the North American physician market.

For more information, visit the company's website at

This news release contains statements that may be considered 'forward- looking statements' within the meaning of the Private Securities Litigation Reform Act. Forward-looking statements by their nature involve substantial uncertainty, and actual results may differ materially from those that might be suggested by such statements. Important factors identified by the Company that it believes could result in such material differences are described in the Company's Annual Report on Form 10-K for the year 2006. However, the Company necessarily can give no assurance that it has identified or will identify all of the factors that may result in any particular forward-looking statement materially differing from actual results, and the Company assumes no obligation to correct or update any forward-looking statements which may prove to be inaccurate, whether as a result of new information, future events or otherwise.

Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells
2. New Enterprise Forum Celebrates 22nd Anniversary, Presents Annual Entrepreneur Awards to Randal Charlton & Others
3. EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study
4. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. BAI Retail Delivery Conference Softpro Presents Next Generation Signature Tablet
7. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
8. Resverlogix Presents Key Apo-Al/HDL Scientific Data at DALM
9. Arpida Presents Preclinical Data on AR-2474 at ICAAC
10. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
11. Sangamo BioSciences Presents Data Demonstrating In Vivo Protection Against HIV Infection by CCR5-ZFN Therapeutic
Post Your Comments:
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/25/2015)... 26, 2015 --> ... 2016 - 2020 report analyzes that automating biobanking ... quality in long-term samples, minimizing manual errors, improving ... minimizes manual errors such as mislabeling or inaccurate ... it plays a vital role in blood fractionation, ...
(Date:11/25/2015)... , November 25, 2015 2 ... première fois les différences entre les souches bactériennes ... celles des êtres humains . Ces recherches ... et envisager la prise en charge efficace de ... diagnostiqués chez les chats .    --> ...
(Date:11/25/2015)... and HOLLISTON, Mass. , Nov. 25, ... HART ), a biotechnology company developing bioengineered organ ... Jim McGorry will present at the LD Micro ... at 2:30 p.m. PT. The presentation will be webcast ... days. Management will also be available at the conference ...
Breaking Biology Technology:
(Date:10/29/2015)... Today, LifeBEAM , a leader ... a global leader in technical performance sports clothing ... advanced bio-sensing technology. The hat will allow fitness ... biometrics to improve overall training performance. As a ... bring together the most advanced technology, extensive understanding ...
(Date:10/27/2015)... 2015 Munich, Germany ... technology (ASGM) automatically maps data from mobile eye tracking ... , so that they can be quantitatively analyzed with ... Munich, Germany , October 28-29, 2015. SMI,s Automated ... mobile eye tracking videos created with SMI,s Eye ...
(Date:10/26/2015)... India , October 26, 2015 ... --> adds ... 2015 to 2021 as well as ... 2015-2019 research reports to its collection ... . --> ...
Breaking Biology News(10 mins):